HWPC(SH:688799) Ge Long Hui A P P·2026-02-12 08:56Core Viewpoint - Warner Pharmaceuticals (688799.SH) has participated in the national organized procurement for drugs whose agreements have expired, with several of its products expected to be selected in this procurement process [1] Group 1: Procurement Details - The procurement involves products from the first to the eighth batch of national organized procurement agreements that have expired, with the purchasing volume based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual implementation date of the selected results [1] Group 2: Financial Impact - A total of 12 products from the company are expected to be selected, with projected sales revenue of 176.18 million yuan for 2024, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 3: Market Implications - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed purchasing volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and enhance the company's brand influence in the domestic market [1]